Gonad Disease Medication Cyproterone Acetate Powder CAS: 427-51-0 High Quality and Safe Delivery

Basic Information
Place of Origin: CHINA
Brand Name: TINGYI
Certification: GMP , ISO 9001:2008
Model Number: 427-51-0
Minimum Order Quantity: 10g
Price: Contact Us
Packaging Details: Stealth And Discreet Packaging
Delivery Time: Within 7 Working Days
Payment Terms: Bank Transfer - Bitcoin - Western Union - MoneyGram
Supply Ability: 50 KG/Month
Product Name: Cyproterone Acetate CAS: 427-51-0
MF: C24H29ClO4 MW: 416.94
EINECS: 207-048-3 Appearance: White Crystalline Solid
High Light:

pharmaceutical active ingredients


pharmaceutical anabolic steroids

Gonad Disease Medication Cyproterone Acetate Powder CAS: 427-51-0 High Quality and Safe Delivery 0


Cyproterone Acetate



Basic Information:

Product Name: Cyproterone Acetate
CAS: 427-51-0
MF: C24H29ClO4
MW: 416.94
EINECS: 207-048-3
Melting point: 200-201°C
storage temp: 2-8°C
appearance: White Crystalline Solid

1. Used as an antiandrogen. Combinded with estrogen in the treatment of acne
2. The free alcohol is an anti-androgen; the acetate is both an anti-androgen and a progestogen. Combined with estrogen it is used in the treatment of acne.
3. antiparasitic, fasciolicide


What is Cyproterone Acetate?

An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.


Certificate of Analysis:

Product name Cyproterone Acetate
CAS No. 427-51-0 Outer Packing 1KG
Production date 2018-06-19 Shelf life 2012-06-19
Standard EP8.0
Items of analysis Specification Results
Characters white or almost white crystalline powder white crystalline powder
Solubility practically insoluble in water, very soluble in methylene chloride, freely soluble in acetone, soluble in methanol, sparingly soluble in anhydrous ethanol. Complies
Identification First identification: A(IR). Second identification: B(TLC), C, D, E. Complies
Specific optical rotation +152°~+157 ° +155.6°
Melting point About 210ºC 208.5~209.5ºC
Impurity F (RRT about 0.5) ≤0.4% 0.12%
Impurity E (RRT about 0.27) ≤0.2% 0.08%
Impurity B (RRT about 0.7) ≤0.15% <0.05%
Impurity C(RRT about 1.5) ≤0.15% <0.05%
Impurity G (RRT about 0.3) ≤0.15% <0.05%
Uninspected impurities ≤0.10% 0.05%
Total impurities ≤0.5% 0.29%
Loss on drying Not more than 0.5% 0.21%
Sulphated ash Not more than 0.1% 0.05%
Assay (UV) 97.0%~103.0% 102.2%
Particle size 100%≤30um complies
Chloroform Not more than 60ppm 45ppm
Ethyl acetate Not more than 5000ppm n.d
Methanol Not more than 3000ppm n.d
Dichloromethane Not more than 600ppm n.d
Acetone Not more than 5000ppm 866ppm
Ethanol Not more than 5000ppm n.d
Conclusion Qualified


Medical Uses:

1. Androgen-dependent conditions

CPA is used in the treatment of prostate cancer, precocious puberty, androgen-dependent skin and hair conditions such as acne, seborrhea, hirsutism (excessive hair growth), and androgenic alopecia (pattern hair loss), hyperandrogenism (e.g., in PCOS), and to reduce sex drive in sex offenders or men with paraphilias or hypersexuality. CPA is also widely used as a component of feminizing hormone therapy for transgender women. In the U.S., where CPA is not available, other drugs with antiandrogen properties like the diuretic spironolactone and the progestin medroxyprogesterone acetate are used instead to treat androgen-dependent conditions besides prostate cancer.

In the treatment of acne in women, a formulation of low-dose CPA in combination with EE has been found to result in overall improvement in 75 to 90% of patients, with responses approaching 100% improvement.


2. Birth control


3. Available forms

CPA is available in the form of oral tablets alone (high-dose; 10 mg, 50 mg, 100 mg) or in combination with ethinylestradiol or estradiol valerate (low-dose; 2 mg CPA) and in the form of ampoules for intramuscular injection (high-dose; 100 mg/mL, 300 mg/3 mL; brand name Androcur Depot). The high-dose formulations are used to treat prostate cancer and certain other androgen-related indications while the low-dose formulations which also have an estrogen are used as combined birth control pills and are used in menopausal hormone therapy for the treatment of menopausal symptoms.


4. Contraindications


5. Use during pregnancy is contraindicated.


Side Effects:

Common side effects of CPA include hypogonadism and associated symptoms like demasculinization, sexual dysfunction, infertility, and osteoporosis, breast changes like gynecomastia, mental changes like depression, anxiety, fatigue, and suicidal ideation, vitamin B12 deficiency, glucocorticoid side effects like stretch marks, and elevated liver enzymes.

At very high dosages, CPA can cause cardiovascular side effects. Rarely, CPA can cause blood clots, liver damage, excessively high prolactin levels, prolactinomas, and meningiomas. Upon discontinuation at high dosages, CPA can have withdrawal effects, namely adrenal insufficiency.

Contact Details
Sales Manager

WhatsApp : +8613657291547